Crossmark

Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

Crossref DOI link: https://doi.org/10.1016/j.abd.2024.04.004

Published Print: 2024-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Mansilla-Polo, Miguel http://orcid.org/0000-0001-6730-6723
Sahuquillo-Torralba, Antonio http://orcid.org/0000-0002-9354-7464
Pujol-Marco, Conrad http://orcid.org/0009-0000-0345-7485
Bargues-Navarro, Guillermo http://orcid.org/0000-0002-9212-0135
Botella-Estrada, Rafael http://orcid.org/0000-0002-6153-8192
License Information

Text and Data Mining valid from 2024-11-01

Text and Data Mining valid from 2024-11-01

Version of Record valid from 2024-07-25
More Information

This article is maintained by: Elsevier

Article Title: Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice

Journal Title: Anais Brasileiros de Dermatologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2024.04.004

Content Type: article

Copyright: © 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below